Mazdutide, also known by the development codes IBI362 and LY3305677, is a long-acting peptide developed from research into dual activation of the GLP-1 and glucagon receptors. Innovent Biologics advanced its clinical development in China, with human studies evaluating its potential for obesity, overweight, and metabolic disease.
Clinical development progressed through multiple Phase 2 and Phase 3 studies. In 2025, China’s National Medical Products Administration approved mazdutide for chronic weight management, making it one of the first dual GLP-1/glucagon receptor agonists to reach regulatory approval.
Mazdutide remains investigational or unapproved in many other jurisdictions, including the United States.
Mazdutide is a dual GLP-1 receptor and glucagon receptor agonist. This combination is intended to influence both sides of energy balance.
GLP-1 receptor activation can:
Glucagon receptor activation may increase energy expenditure and lipid metabolism, although glucagon also has glucose-raising effects. The drug is therefore engineered to balance these pathways rather than simply maximizing either receptor independently.
This mechanism distinguishes mazdutide from conventional GLP-1-only therapies.
Mazdutide has primarily been investigated for chronic weight management and metabolic disease. Clinical studies have examined outcomes including body weight, waist circumference, blood glucose, HbA1c, blood pressure, blood lipids, and liver-related metabolic markers.
Its potential role in metabolic dysfunction-associated steatotic liver disease (MASLD) is also of research interest because substantial weight reduction and improved metabolic health can reduce liver fat.
Clinical monitoring for drugs in this class generally focuses on metabolic and cardiovascular parameters rather than attempting to establish a single universal “safe range.”
Important measurements may include:
| Biomarker | Why It Matters |
|---|---|
| HbA1c / Fasting Glucose | Tracks glycemic status and response |
| Lipid Panel | Evaluates triglycerides, LDL and other cardiometabolic markers |
| Liver Tests | Helps assess baseline and changing hepatic health |
| Blood Pressure | Weight loss may improve BP, while individual responses vary |
| Resting Heart Rate | GLP-1–based therapies can modestly increase heart rate |
| Kidney Function | Particularly relevant if significant vomiting or dehydration occurs |
Mazdutide should not be treated as interchangeable with another GLP-1 medication simply because they share GLP-1 receptor activity.
Combining incretin-based therapies without clinical justification may increase gastrointestinal or metabolic adverse effects and has not been established as a superior approach.
Mazdutide has been studied as a once-weekly subcutaneous medication. Clinical trials generally use structured dose-escalation strategies rather than immediately beginning participants at the highest target dose.
The purpose of gradual escalation is particularly important with incretin-based drugs because gastrointestinal adverse effects tend to be more prominent during initiation and dose increases.
Specific dosing schedules differ between clinical trials, approved regional labeling, and the population being studied. Consequently, research-study doses should not automatically be converted into self-directed treatment protocols.
Similarly, clinical trial publications should not be interpreted as instructions for reconstituting independently sourced peptide material. Commercial or research preparations can differ in concentration, formulation, excipients, sterility, and stability.
Clinical trials have demonstrated clinically meaningful reductions in body weight with mazdutide, with larger reductions generally occurring at higher studied doses and over longer treatment periods.
The exact percentage varies according to trial design, dose, treatment duration, baseline characteristics, and whether the analysis includes all randomized participants or only those completing treatment.
Reductions in waist circumference have accompanied weight loss, suggesting reductions in abdominal adiposity.
Mazdutide has also demonstrated improvements in measures such as fasting glucose and HbA1c, making its metabolic effects relevant beyond body weight alone.
Studies have reported improvements in several cardiovascular risk markers, including blood pressure and lipid measurements.
These improvements are promising, but improvements in risk factors should not be described as proof that mazdutide prevents heart attacks or strokes. Dedicated cardiovascular-outcomes evidence is required to establish those conclusions.
As with other medications that strongly activate GLP-1 receptors, the most frequently reported adverse effects are gastrointestinal.
Commonly reported effects include:
A modest increase in resting heart rate has also been observed with drugs in this therapeutic area.
Adverse effects often occur more frequently during dose escalation, which is one reason clinical protocols generally increase exposure gradually.
Persistent vomiting or diarrhea deserves particular attention because it can cause dehydration and electrolyte disturbances and may contribute to kidney complications.
Clinical response is a balance between efficacy and tolerability. Increasing exposure can increase adverse effects as well as therapeutic effects.
Not quite. Its glucagon-receptor activity is a defining part of its pharmacology.
Weight, blood pressure, glucose, and lipid improvements are encouraging cardiovascular risk-factor changes, but they are not equivalent to demonstrating fewer cardiovascular events.
They are not. Trial drugs are manufactured and controlled under pharmaceutical development standards. Independently sourced material cannot automatically be assumed to have equivalent identity, purity, concentration, sterility, or pharmacokinetics.
Obesity is increasingly treated as a chronic disease, so the clinical question is generally not simply how to “cycle off” a medication.
Appetite regulation and other pharmacological effects diminish after treatment ends. Weight regain can occur after discontinuing effective anti-obesity pharmacotherapy, particularly when the biological drivers of obesity remain present.
Long-term treatment decisions therefore need to balance effectiveness, tolerability, metabolic health, lifestyle, cost, and individual medical considerations.
There is no evidence-based universal “exit protocol” that applies to every person using mazdutide.
Mazdutide is already a multi-receptor therapy, activating both GLP-1 and glucagon receptors.
That makes unsupervised combination with additional GLP-1 receptor agonists particularly questionable. More receptor activation does not necessarily translate into greater clinical benefit and can increase adverse effects.
Lifestyle interventions remain important alongside pharmacotherapy. Resistance training and adequate dietary protein are particularly relevant during substantial weight reduction because weight loss can involve both fat and lean tissue.
Future research may determine whether specific drug combinations provide additional benefits, but experimental combinations should be clearly distinguished from established clinical practice.
Mazdutide trials have reported improvements in several cardiometabolic risk factors, including body weight, blood pressure, glucose regulation, and lipid parameters.
These results are encouraging but should not yet be translated into claims that mazdutide directly prevents heart failure, myocardial infarction, or stroke without appropriate outcomes evidence.
Mazdutide has demonstrated glucose-lowering effects and has been investigated in people with metabolic disease. Because glucose-lowering medications can interact, people using insulin or other diabetes medications require individualized medical management.
One particularly interesting research area is liver fat and MASLD. Weight reduction and improvements in insulin sensitivity can substantially influence hepatic fat accumulation, and clinical research is evaluating mazdutide’s effects in this area.
Claims that it “reduces liver fat by 80%” should always identify the specific study, population, dose, measurement technique, and endpoint rather than presenting the figure as a universal outcome.
Evidence in people with significant renal impairment remains more limited than evidence from general obesity populations. Dehydration caused by severe gastrointestinal adverse effects is also an important consideration for kidney health.
There is currently insufficient evidence to characterize mazdutide as either preventing or treating cancer.
As with other GLP-1–based drugs, preclinical thyroid C-cell findings require careful distinction from demonstrated human cancer risk. People with relevant personal or family medical histories should discuss those issues with a qualified clinician.
Upper-respiratory infections have been reported during some clinical studies, but their occurrence does not establish that mazdutide either causes respiratory infections or protects against them.
Mazdutide is a long-acting dual GLP-1/glucagon receptor agonist representing an important evolution in metabolic pharmacology. Instead of focusing exclusively on appetite suppression, its design combines GLP-1-mediated effects on food intake and glucose regulation with glucagon-receptor activity that may influence energy expenditure and lipid metabolism.
Clinical trials have produced encouraging results involving body weight, waist circumference, glucose regulation, blood pressure, and lipid markers. Its development also highlights the growing interest in multi-receptor medicines for obesity and related metabolic disorders.
At the same time, several claims surrounding mazdutide should be interpreted carefully. Improvements in cardiovascular risk factors do not automatically establish cardiovascular-event prevention, experimental combinations should not be treated as validated protocols, and clinical-trial doses should not be converted into instructions for independently sourced research material.
Mazdutide’s regulatory status also varies geographically. Readers should distinguish between approval in China and investigational status in other markets rather than describing it simply as universally “approved” or “unapproved.”
Overall, mazdutide provides an important example of where next-generation obesity pharmacology is heading: multi-receptor therapies designed to simultaneously influence appetite, glucose metabolism, energy expenditure, and broader cardiometabolic health.
Disclaimer: This article is for educational and research-information purposes only. It is not medical advice, diagnosis, prescribing guidance, or a self-administration protocol. Regulatory status and approved indications vary by country. Treatment decisions involving prescription or investigational metabolic therapies should be made with an appropriately qualified healthcare professional.
CHAPTER 1: OVERVIEW 📋 I. History of VIP 🏛️ Vasoactive Intestinal Peptide (VIP) is a naturally occurring 28-amino-acid neuropeptide first isolated in 1970 by Sami
The modern anti-obesity landscape has been revolutionized by incretin mimetics like semaglutide and tirzepatide. While these therapies routinely produce weight reductions of 20 to 40
As the race for next-generation obesity and metabolic treatments intensifies, Eli Lilly’s triple agonist retatrutide (targeting GLP-1, GIP, and glucagon receptors) has dominated headlines. However,
CHAPTER 1: OVERVIEW I. History of ARA-290 (Cibinetide) ARA-290, also known as cibinetide, is an 11-amino-acid peptide derived from a tissue-protective region of erythropoietin (EPO).
CHAPTER 1: OVERVIEW 📋 I. History of Cagrilintide 🏛️ Cagrilintide is an investigational, long-acting analog of amylin, a hormone naturally released by pancreatic beta cells
CHAPTER 1: OVERVIEW 📋 I. History of Delta Sleep-Inducing Peptide (DSIP) 🏛️ Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring nonapeptide composed of nine amino
